共 28 条
[3]
Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline
[J].
JOURNAL OF CLINICAL ONCOLOGY,
2016, 34 (20)
:2416-U186
[6]
Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/S0140-6736(16)31891-8, 10.1016/s0140-6736(16)31891-8]
[7]
Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With HER2/CEP17 Ratio <2.0 and Average HER2 Copy Number ≥4.0 and <6.0
[J].
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE,
2020, 144 (05)
:597-601
[9]
High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predict Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer
[J].
ONCOLOGIST,
2016, 21 (01)
:21-27